| Fish oil in the treatment of dyslipidemia. | |
| | |
MedLine Citation:
|
PMID: 18316953 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: The recent availability of a concentrated prescription omega-3 fatty acid preparation provides physicians with an additional anti-dyslipidemic agent at a time when limitations of statin therapy in dyslipidemic high-risk patients are recognized. This review examines the evidence supporting the use of omega-3 fatty acid treatment in dyslipidemic states. RECENT FINDINGS: There is now considerable evidence that omega-3 fatty acid treatment at the prescription strength of 4 g/day effectively and safely lowers triglyceride levels and increases low-density lipoprotein size, as well as affecting high-density lipoprotein metabolism. Similar effects have been noted in patients treated with statins, and add-on prescription omega-3 fatty acid therapy significantly increases the proportion of statin-treated dyslipidemic patients reaching their non-high-density lipoprotein cholesterol goals. In addition to past studies showing a cardioprotective effect of low-dose omega-3 fatty acid treatment against sudden death, a recent controlled clinical trial showed that 1.8 g of omega-3 fatty acid in statin-treated patients reduced major coronary events by 19% compared with statin plus placebo treatment. SUMMARY: Omega-3 fatty acid treatment should be considered in patients with severe hypertriglyceridemia as well as in high-risk patients with an atherogenic lipoprotein phenotype. |
| | |
Authors:
|
Ronald B Goldberg; Anup K Sabharwal |
Related Documents
:
|
9555103 - Distinctive inhibitory activity of docosahexaenoic acid against sphingosine-induced apo... 16698313 - Docosahexaenoic acid enrichment can reduce l929 cell necrosis induced by tumor necrosis... 16656923 - Does ethylene mediate root growth inhibition by indole-3-acetic acid? |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in endocrinology, diabetes, and obesity Volume: 15 ISSN: 1752-2978 ISO Abbreviation: - Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-03-04 Completed Date: 2008-04-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101308636 Medline TA: Curr Opin Endocrinol Diabetes Obes Country: England |
Other Details:
|
Languages: eng Pagination: 167-74 Citation Subset: IM |
Affiliation:
|
Division of Endocrinology and Metabolism, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. rgoldber@med.miami.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antilipemic Agents
/
therapeutic use Atherosclerosis / prevention & control Cardiovascular Diseases / complications, drug therapy Dyslipidemias / drug therapy* Fatty Acids, Omega-3 / therapeutic use Fish Oils / therapeutic use* Humans Lipoproteins / blood, drug effects Lipoproteins, VLDL / blood, drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antilipemic Agents; 0/Fatty Acids, Omega-3; 0/Fish Oils; 0/Lipoproteins; 0/Lipoproteins, VLDL |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inpatient insulin therapy.
Next Document: Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk ...